Zentalis Pharmaceuticals, Inc. 8-K

What Happened
Zentalis Pharmaceuticals, Inc. announced on May 5, 2026 (via an 8-K and press release), that the first patient has been dosed in ASPENOVA, a Phase 3 randomized, confirmatory trial of azenosertib in Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC). The trial is designed to support full approval of azenosertib and follows FDA feedback on requirements for accelerated‑approval conversion.

Key Details

• First patient dosed: announced May 5, 2026 (press release furnished as Exhibit 99.1).
• Trial size and design: approximately 420 patients; randomized, confirmatory Phase 3.
• Treatment arms: azenosertib monotherapy 400 mg QD on a 5 days on / 2 days off schedule (5:2) vs investigator’s choice single‑agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan).
• Regulatory context: trial design informed by FDA feedback to support accelerated approval and potential conversion to full approval, subject to results.

Why It Matters
This marks Zentalis’ advancement of azenosertib from earlier studies into a pivotal Phase 3 trial—an important clinical and regulatory milestone that could lead to full approval if ASPENOVA confirms benefit. For investors, the trial’s enrollment pace, safety and efficacy readouts, and eventual regulatory interactions will be key value drivers. The company’s 8‑K also includes standard forward‑looking statements and cautions about risks (trial outcomes, funding needs, regulatory uncertainty, etc.), which investors should consider when assessing potential impact.